Alembic has received the Food and Drug Administration's nod for doxycycline hyclate delayed-release tablets.
The product is the generic of Mayne's Doryx tablets.
[Read more: Alembic obtains FDA nod for 2 generics]
It is indicated to reduce the development of drug-resistant bacteria.
Doxycycline hyclate delayed-release tablets have a market value of roughly $10 million for the 12 months ending September 2021, according to IQVIA.
[Read more: Alembic debuts generic Zebeta]